

Natco Pharma gets USFDA EIR for Telangana plant

06 August 2019 | News

NATCO receives establishment inspection report for Kothur facility



Natco Pharma Limited is pleased to announce successful closure of inspection with the receipt of Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for the inspection conducted at its drug formulations facility in Kothur Village, Telangana, India, during the period May 30th – June 5th, 2019.

Natco Pharma Limited was incorporated in Hyderabad in the year 1981. With a modest beginning of operations as a single unit with 20 employees, Natco has seven manufacturing facilities spread across India with modern research laboratories, capabilities in new drug development, etc.

Natco, currently consists of around 5,000 employees and is consistently ranked among fastest growing pharmaceutical companies in India and is well recognized for its innovation in pharmaceutical research and development.

In FY 2018-19, NATCO recorded consolidated total revenue of INR 22,247 million as against INR 22,424 million for the last year. The net profit for the period, on a consolidated basis, was INR 6,444 million, as against INR 6,962 million last year.